Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating nivolumab with or without ipilimumab in younger patients with recurrent or refractory solid tumors or sarcomas; completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Hodgkin Lymphoma
• Malignant Solid Neoplasm
• Melanoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Rhabdomyosarcoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-01-10